Funder: National Institutes of Health

Due Dates: June 16, 2025 (New) | July 16, 2025 (Renewal/Resubmission/Revision) | October 16, 2025 (New) | November 16, 2025 (Renewal/Resubmission/Revision) | February 16, 2026 (New) | March 16, 2026 (Renewal/Resubmission/Revision) | June 16, 2026 (New) | July 16, 2026 (Renewal/Resubmission/Revision) | October 16, 2026 (New) | November 16, 2026 (Renewal/Resubmission/Revision) | February 16, 2027 (New) | March 16, 2027 (Renewal/Resubmission/Revision) | June 16, 2027 (New) | July 16, 2027 (Renewal/Resubmission/Revision) | October 16, 2027 (New) | November 16, 2027 (Renewal/Resubmission/Revision)

Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year; project period up to 2 years.

Summary: Supports exploratory research to develop innovative screening methods and therapies for newborns with fatal or disabling disorders, including high-priority genetic conditions not yet on screening panels.

Key Information: Clinical trials are optional; foreign and domestic applicants are eligible; Data Management and Sharing Plan required.